ConductScience.org, home

Library / Genes

CD200: CD200 molecule

1 protein, 101 patents, 1 drug, 2 trials, 2,162 NIH grants and 4,952 papers.

Gene 7

Its symbol and name are HGNC's, unless HGNC and NCBI Gene contradict each other.

FieldValueSource
SymbolCD200HGNC
NameCD200 moleculeHGNC
NCBI Gene ID4345NCBI Gene
HGNC IDHGNC:7203HGNC
EnsemblENSG00000091972NCBI Gene
AliasesMOX1, MOX2, MRC, OX-2NCBI Gene
Typeprotein-codingNCBI Gene

Proteins 1

Reviewed human proteins whose Swiss-Prot entry states the gene.

UniProt entryProteinLengthStructuresGene stated inSource
P41217OX-2 membrane glycoprotein2780Ensembl, GeneID, HGNCUniProt

Patents 101

Patents whose sequence listing holds the protein exactly: the same sequence, by SHA-256, length and CRC-64. A sequence a patent lists is not always one it claims.

PublicationPublishedSEQ ID NOProteinSource
EP 4831196 A22026-10-2825P41217Espacenet
US 12624087 B22026-05-1225P41217Espacenet
US 12612446 B22026-04-28466P41217Espacenet
WO 2025228986 A12025-11-0657P41217Espacenet
EP 4644537 A12025-11-0557P41217Espacenet
JP 2025166053 A2025-11-0525P41217Espacenet
JP 2025163187 A2025-10-286P41217Espacenet
JP 2025148471 A2025-10-07466P41217Espacenet
JP 2025138715 A2025-09-2525P41217Espacenet
JP 2025529142 A2025-09-04785P41217Espacenet

Drugs 1

Drugs a ChEMBL mechanism record says act on the gene's protein, through Open Targets.

DrugChEMBL IDMechanismActionSource
SAMALIZUMABCHEMBL1743067OX-2 membrane glycoprotein inhibitorINHIBITORChEMBL

Trials 2

Trials of those drugs. A trial joins the gene only through a drug that acts on it.

TrialDrugPhaseResults first postedSource
NCT03013998SAMALIZUMABPHASE1/PHASE2ClinicalTrials.gov
NCT00648739SAMALIZUMABPHASE1/PHASE22019-03-05ClinicalTrials.gov

NIH grants 2162

NIH projects whose papers are about the gene, through NIH's grant-paper links.

ProjectTitleIts papers about the geneNewest fiscal yearSource
P30CA016672Cancer Center Support Grant212,025NIH's project files
P30CA008748Cancer Center Support Grant162,025NIH's project files
U19AI082630Durable Alteration of the Human Immune system after Infection or Immunotherapy162,025NIH's project files
P30CA016058Cancer Center Support Grant102,025NIH's project files
P30CA021765Cancer Center Support Grant (CCSG)102,025NIH's project files
P51OD011132Emory National Primate Research Center102,025NIH's project files
P51OD011092Support for National Primate Research Center92,025NIH's project files
P30CA015704Cancer Center Support Grant82,025NIH's project files
P01AI108545Synergies among inhibitory receptors in tolerance and disease72,025NIH's project files
P30AG066519The Alzheimer's Disease Research Center at the University of California, Irvine62,025NIH's project files

Papers 4952

Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.

PMIDFound bySource
42798844PubTator, text miningPubMed
42793125PubTator, text miningPubMed
42783079PubTator, text miningPubMed
42776280PubTator, text miningPubMed
42761652PubTator, text miningPubMed
42700883PubTator, text miningPubMed
42683229PubTator, text miningPubMed
42664786PubTator, text miningPubMed
42662104PubTator, text miningPubMed
42604388PubTator, text miningPubMed

The same record as JSON

Release gene-search-2026-11-11-0.1.0

ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

ChEMBL, through Open Targets: CC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

EMBL-EBI's patent proteins: EMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use

GenBank's patent files: GenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/

HGNC: CC0: https://www.genenames.org/about/license/

NCBI Gene: None named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/

NIH's project files and grant-paper links: Public domain (NIH RePORTER)

Open Targets: CC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence

PubTator 3: Public domain

UniProt: CC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license